BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
海角七号
发表于 昨天 21:43
117
0
0
Blue Whale News, September 12th (Reporter Tu Jun) Following the patent infringement lawsuit filed by AbbVie in June last year regarding its core product BTK inhibitor Baiyueze (Zebutinib Capsules), it has been reported that pharmaceutical giant AbbVie once again sued BeiGene last Friday. The former sued BeiGene in the Federal Court of Chicago, accusing it of stealing trade secrets to develop competitive anti-cancer therapies after hiring a former senior scientist from AbbVie.
It is reported that the above-mentioned project includes the compound BGB-16673 independently discovered by BeiGene researchers through years of innovative research.
On August 27th, BeiGene announced that the US FDA has granted BGB-16673 fast track eligibility for the treatment of adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously received at least two lines of treatment, including BTK inhibitors and BCL2 inhibitors. BGB-16673 is an orally administered, BTK targeted chimeric degradation activating compound (CDAC) under development.
BeiGene has stated to Blue Whale Finance that it will provide a firm defense against the allegations made by AbbVie. BeiGene denies this accusation and will firmly defend its intellectual property rights against the lawsuit.
We believe that the lawsuit intends to impede the development process of BGB-16673, which is currently the fastest progressing BTK degradation agent in clinical development. BeiGene had already applied for a patent for BGB-16673 several years before AbbVie first applied for a BTK degradation agent patent BeiGene said.
So far, over 300 patients from 15 countries and regions have received treatment in the BGB-16673 global clinical development project.
BeiGene stated that the focus on advancing the BGB-16673 development project will not be interrupted by this lawsuit, and the drug has the potential to become an important treatment option for patients with disease progression and limited choices after using BTK inhibitors.
Affected by the news, BeiGene's A-shares fell 10.61% today (September 12th) to HKD 144.01 per share, while Hong Kong stocks fell 5.44% to HKD 118.3 per share.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- TSMC's Q2 financial report exceeded expectations in all aspects, with a focus on expanding production of advanced processes and increasing annual capital expenditures
- BeiGene: Chief Financial Officer Wang Aijun will resign on July 19th
- Intel: Intel18A chip process product successfully lit up
- Company Review | BeiGene has suffered continuous losses in the past 7 years, and its stock price is under pressure. Can the new CFO bring a turning point?
- More than 40% reduction in losses in the first half of the year, but multiple peers have achieved profits. BeiGene is facing increasing peer pressure
- Strong Apple A18 orders drive TSMC's 3nm process to increase revenue by 34% year-on-year this year
- AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- BeiGene denies AbbVie's accusation of "stealing trade secrets": will launch a firm defense and development projects will not be interrupted as a result
-
人気の中概株の上昇と下落はまちまちで、ナスダック中国金龍指数は0.06%上昇し、今週の累計は1.03%上昇した。蔚来は5%超上昇した。
- SOHU
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
現地時間の9月12日、米株3大指数は集団で上昇し、納指は1%上昇し、スタンダード500指数は0.75%、ダウは0.58%上昇した。このうち、納指、スタンダード500指数はいずれも4日連続で上昇した。 大型科学技術株は普遍的 ...
- SOGO
- 昨天 01:58
- 支持
- 反对
- 回复
- 收藏
-
金利低下周期と中東情勢の上昇に後押しされて、国際金価格は上昇を続けている! 9月20日、現物金価格は初めて2600ドルを突破し、史上記録を更新した。ロンドンの現物金は1.37%上昇し、2621.5286ドル/オンスを報告し ...
- SOHU
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
ウォールストリートジャーナルによると、世界最大のチップメーカー2社の台積電と三星電子は今後数年間にアラブ首長国連邦でチッププロジェクトを建設することを検討している可能性があり、プロジェクトの価値は1000 ...
- 寒郁轩良
- 前天 10:39
- 支持
- 反对
- 回复
- 收藏